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KidneyCOVID-19 Vaccine Hesitancy in Patients
on Dialysis in Italy and FranceSophie Blanchi1,9, Massimo Torreggiani2,9, Antoine Chatrenet2,3, Antioco Fois2,
Béatrice Mazé2, Linda Njandjo2, Giovanna Bianco4, Nicola Lepori4, Alessio Pili4,
Pierre-Antoine Michel5, Giuseppe Sileno6, Marta Arazzi6, Vittoria Esposito6, Antonello Pani7,
Elisabetta Versino8, Ciro Esposito6,9, Hafedh Fessi5,9, Gianfranca Cabiddu7,9 and
Giorgina Barbara Piccoli2,9
1Department of Infectious Diseases, Centre Hospitalier Le Mans, Le Mans, France; 2Néphrologie et Dialyse, Centre Hospitalier
Le Mans, Le Mans, France; 3Laboratory “Movement, Interactions, Performance” (EA 4334), Le Mans University, Le Mans,
France; 4Unit of Nephrology, San Michele Hospital, ARNAS G. Brotzu, Cagliari, Italy; 5Department of Nephrology, Hospital
Tenon, Paris, France; 6Nephrology and Dialysis, ICS Maugeri SpA SB, Pavia, Italy; 7Department of Medical Science and Public
Health, University of Cagliari, Nephrology, San Michele Hospital, ARNAS G. Brotzu, Cagliari, Italy; and 8Department of Clinical
and Biological Sciences, University of Torino, Torino, ItalyIntroduction: Patients on dialysis (HDPs) are a category at high risk from COVID-19 and thus a high-priority
group for vaccination. COVID-19 vaccine hesitancy has been a concern since the availability of the first
vaccine. The objective of this study was to determine hesitancy rates and factors associated with hesitancy
toward COVID-19 vaccination in HDP.
Methods: HDP were surveyed with an ad hoc questionnaire in 4 large dialysis facilities in Europe: Le Mans
and Paris, in France, and Cagliari and Pavia, in Italy. The questionnaire explored different domains
associated with vaccine hesitancy, such as perception of disease severity, sources of information about
the vaccine and the disease, and confidence in the health care system.
Results: A total of 417 patients (average age 69 years, 60% men) agreed to answer the questionnaire.
Hesitancy was associated with younger age (P ¼ 0.003), lower perception of disease severity (P < 0.001)
and vaccine efficacy (P < 0.001), and lower trust in vaccination (P < 0.001) and in the health care system
and scientists (P < 0.001) in the univariate analysis. In the multivariate models, concerns about side effects
(P ¼ 0.004) and vaccine efficacy (P < 0.001) and living in France (P ¼ 0.04) remained associated with higher
vaccine hesitancy, whereas having received an influenza vaccine (P ¼ 0.032) and trusting scientists (P ¼
0.032) were associated with a more positive attitude toward vaccination.
Conclusions: HDPs have a good understanding of the risks associated with COVID-19. Vaccine hesitancy
was not associated with educational level, age, or gender but rather with lack of confidence in vaccine
efficacy and concerns about safety. HDPs were quite skeptical about the health care system but generally
trusted scientists.
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he COVID-19 epidemic had highlighted the
fragility of some groups, in particular elderly
and high-comorbidity individuals.1 The fragility of pa-
tients on dialysis, in combination with immunodepres-
sion, high morbidity, and older age, is well
acknowledged. During the first year of the pandemic,spondence: Giorgina B. Piccoli, Nephrology and Dialysis,
Hospitalier Le Mans, 194 Ave Rubillard, 72000, Le Mans,
e. E-mail: gbpiccoli@yahoo.it
T, EV, CE, HF, GC, and GBP contributed equally to the
.
ved 5 July 2021; revised 26 August 2021; accepted 30 August
International Reports (2021) -, -–-their fragility, plus the need for regular visits to often
crowded dialysis wards, resulted in a high rate of infec-
tion in patients on dialysis (a cumulative incidence of
more than 14% in France and in Italy), with high mor-
tality (between 15% and 20% of all cases).2–4
On April 8, 2021, the European Medicines Agency
(EMA) granted conditional marketing authorization to 4
COVID-19 vaccines: 2 mRNA vaccines, Comirnaty
(Pfizer/BioNTech) and COVID-19 Vaccine Moderna; and
2 nonreplicative viral vector vaccines, Vaxzevria (Astra
Zeneca) and COVID-19 Vaccine Janssen. Starting in
January 2021, patients on dialysis in France were
identified by the Haute Autorité de Santé (HAS) as a1
CLINICAL RESEARCH S Blanchi et al.: COVID-19 Vaccine Hesitancypriority population for vaccination against SARS-CoV-2.
The HAS in France and Italy’s Ministero della Salute
recommends prioritizing the vaccination for people at a
very high risk of death, including dialysis and kidney
transplant patients, regardless of their age.5,6 The use of
mRNA vaccines is preferred for these patients. COVID-
19 vaccines are free of charge in both countries.
However, the availability of vaccines and their
acknowledged priority by the health authorities has
not guaranteed vaccine acceptance.
In 2019, the WHO identified vaccine hesitancy as
one of the 10 most serious threats to global health.7
Vaccine hesitancy is defined as “delay in acceptance
or refusal of vaccines despite availability of vaccine
services.” This phenomenon is of particular concern in
Western Europe.
Several factors have been identified as being asso-
ciated with COVID-19 vaccine acceptance in the general
population: perception of the seriousness of the infec-
tion, perception of the risk of infection for oneself and
one’s family, trust in the health care system, trust in
the information given by doctors, trust in vaccine
research, vaccine safety, vaccine effectiveness, having
received a flu vaccine, male gender, white ethnicity,
educational level, income level, urban versus rural
living, and older age.8–14 People with comorbidities at
risk of severe COVID-19 were found more likely to
accept a COVID-19 vaccine.12,13 However, COVID-19
vaccine refusal remains high: in a recent US study,
less than half the respondents between 18 and 64 years
of age with underlying medical conditions replied that
they would be likely to receive a COVID-19 vaccine.14
To date, only 1 study on COVID-19 vaccine hesi-
tancy in patients on dialysis has been conducted. Done
in the United States, its findings related hesitancy to
younger age, female gender, and some ethnic groups.15
In-depth knowledge about the perceived barriers to
vaccination is, however, crucial for acceptance, and
because there is likely to be a significant degree of
vaccine hesitancy in the dialysis population, every-
thing possible should be done to obtain a high rate of
vaccine coverage and protect this community.
Given that this is so, we designed this international
multicenter study to assess COVID-19 vaccine hesitancy
rates in patients on dialysis in 4 large dialysis facilities in
Italy and France, with 1 center in each country in a rural
area and 1 in a city, in order to identify factors associ-




Centre Hospitalier du Mans (CHM), one of the 3 largest
nonuniversity hospitals in France, has about 1700 beds,2
500 of them in geriatric units and about 300 for
different medical specialties (20 in nephrology). Le
Mans has about 150,000 inhabitants, with approxi-
mately another 150,000 people living in its suburbs;
CHM serves a population of about 800,000 inhabitants.
Two dialysis facilities run by a nonprofit association
(ECHO) are present in the area but nephrology beds are
only available at CHM. Patients on peritoneal dialysis
are managed conjunctly and were not included in the
present survey. The dialysis ward has 25 beds. These
are occupied by chronic patients on dialysis, patients
with acute kidney injury (AKI), and patients from out-
of-hospital centers who need to be hospitalized. The
pool of patients on chronic hemodialysis ranges from 95
to 110, depending on the incidence of kidney trans-
plantation, deaths, and transfers. In keeping with the
indications of the French Society of Nephrology (Soci-
été Francophone de Néphrologie, Dialyse et Trans-
plantation [SFNDT]), out-of-hospital dialysis is widely
used and only cases posing particular clinical, attitu-
dinal, or psychological problems are managed in the
hospital. Hence, the population studied is a large
sample of the most difficult patients treated in the area.
The ratio between cases treated at CHM and those
treated at the nonprofit association is around 1:6.
All physicians without contraindications and all the
nurses working in dialysis (7 nephrologists and all the
nurses) had received at least 1 dose of the vaccine at the
time the survey began.
Cagliari
The study was conducted at Azienda Ospedaliera
Brotzu, the largest hospital in Sardinia, Italy’s largest
island. The hospital has about 677 beds (24 in the
nephrology ward) and a transplant center, performing
35 to 40 kidney grafts per year. Cagliari has a popu-
lation of about 150,000 inhabitants, which rises to
420,000 if those living in districts surrounding the city
are counted, and the entire area Ospedale Brotzu serves
has a population of about 800,000. Nephrology beds are
available only in the hospital. A network of public out-
of-hospital dialysis facilities provides treatment for
patients with lower comorbidity, in keeping with
Italian practice. The ratio between patients treated at
Ospedale Brotzu and those receiving dialysis in out-of-
hospital settings is around 1:6.
The dialysis unit has 26 beds dedicated to chronic
patients and 8 for patients from other units with AKI or
CKD, requiring hospitalization. The pool of patients on
chronic treatment ranges from 90 to 100, depending on
kidney transplantation, deaths, and transfers. Between
50 and 55 peritoneal patients on dialysis are also fol-
lowed in the unit (monthly clinical visits in the center).
All physicians and 87% of the nurses working inKidney International Reports (2021) -, -–-
S Blanchi et al.: COVID-19 Vaccine Hesitancy CLINICAL RESEARCHdialysis had received at least 1 dose of the vaccine
when the survey began.
Pavia
The Maugeri Institute is the leading Italian group in
rehabilitation medicine and in the treatment of chronic
fragile patients, with 18 institutes located throughout
the country. The Maugeri Institute in Pavia has about
306 beds, 100 of which are for acute clinical conditions
in different medical specialties (at the time of the study,
12 in the nephrology unit). Pavia has about 73,000
inhabitants with approximately another 470,000 people
living in outlying districts. The Institute serves a
population of about 200,000. Three public hospitals
with dialysis facilities are present in the area. The
Maugeri Institute’s dialysis center is the largest in the
district and nephrology beds are available there and at
a nearby public hospital. Maugeri’s dialysis ward has
36 beds. They are occupied mainly by chronic patients
on dialysis and patients from other centers who need
rehabilitation treatment. The pool of patients on
chronic treatment ranges from 120 to 140 depending on
the incidence of kidney transplantation, deaths, and
transfers. In keeping with the indications of the Italian
Society of Nephrology, out-of-hospital dialysis is
widely used, and only cases posing particular clinical,
attitudinal, or psychological problems are managed in
the hospital. Hence, the population studied is a large
sample of the most difficult patients treated in the area.
The ratio between cases treated at ICS Maugeri and
those treated in the public dialysis unit is around 1:4.
All the physicians and 96% of the nurses working in
dialysis (8 nephrologists, 34 nurses, and 4 helpers) had
received 2 doses of Comirnaty vaccine, completing the
vaccination program when the survey began.
Paris
Hôpital Tenon (Groupe Hospitalier Sorbonne Uni-
versité), one of 9 nephrology university hospitals in Ile
de France, has 525 beds, 60 in geriatric units, and about
300 for different medical specialties (at the time of the
study, 33 in the nephrology unit, and 8 in the
nephrology intensive care unit). Hôpital Tenon serves a
population of about 400,000. The dialysis ward has 24
in-center beds and 5 training home-hemodialysis beds.
These are occupied by chronic patients on dialysis,
patients with AKI (not needing intensive care), as well
as by patients from out-of-hospital centers who need to
be hospitalized. The pool of patients on chronic in-
center treatment ranges from 80 to 100, depending on
the incidence of kidney transplantation, deaths, and
transfers. The pool of patients on home hemodialysis
ranges from 55 to 65. All physicians and 80% of the
nurses working in dialysis (5 nephrologists and 45Kidney International Reports (2021) -, -–-nurses and helpers) had received at least 1 dose of the
vaccine when the survey began.
Patient Participation
In the 4 centers in which the study was carried out, all
patients on chronic dialysis without dementia and
without language barriers that would impair basic
comprehension of the questions were asked to partici-
pate. All patients were outpatients and none was hos-
pitalized when the questionnaire was administered.
Each center distributed the questionnaire according to
their usual way of proposing questionnaires to pa-
tients. In detail, in Le Mans, the questionnaires were
introduced by the caregivers and patients were free to
complete them in the dialysis ward or at home, or,
alternatively, to complete them with the help of a
clinical research assistant, during, before or after their
dialysis session. The last of these was the preferred
modality: owing to advanced age and social isolation,
many patients had become accustomed to completing
questionnaires (mainly periodic assessments of
their quality of life) in the unit with help from nurses
or clinical research assistants. In Le Mans, the
questionnaires—distributed about 3 weeks before the
start of the vaccination campaign—were the first step
in an educational program, whose target was to give
patients information on COVID-19 vaccines.
In Cagliari and Pavia, the questionnaires were pro-
posed by the senior physician and completed by pa-
tients, generally with some help from the residents. In
both settings, the questionnaire was administered 4 to
6 weeks before vaccination had started. In Cagliari,
patients had occasionally been asked in the past to
participate in observational studies requiring the
completion of a questionnaire, and in these cases the
preferred way to answer was with assistance from
caregivers. In Paris, the questionnaire was proposed
just a few days before the start of the vaccination
program in the dialysis ward. Patients there had never
before been asked to participate in a survey. The
questionnaires were introduced by residents or, in the
case of home hemodialysis patients, by nurses.
Although patients were given the choice of being given
assistance to complete the questionnaire during their
dialysis session, the majority preferred to answer at
home, and return the completed survey afterward.
Clinical Data
In all 4 participating centers, patients’ general data are
stored in dedicated databases. The following informa-
tion was gathered for the current analysis: age, gender,
country of birth, native language(s), educational level,
working status, cause of end-stage kidney disease,
Charlson comorbidity index (CCI), date of start of3
CLINICAL RESEARCH S Blanchi et al.: COVID-19 Vaccine Hesitancydialysis, dialysis vintage, previous transplantation,
type of dialysis, and number of dialysis sessions per
week (hemodialysis) or of daily exchanges in peritoneal
dialysis.
Questionnaires
A team of infectiologists and nephrologists at CHM in Le
Mans designed a questionnaire to collect information on
whether patients on dialysis intended to be vaccinated
and identify obstacles to vaccination (available in the
Supplementary Material). The development of this
questionnaire was based on a literature review of
identified barriers to vaccination in general and to
vaccination against SARS-CoV-2.8–14,16 Besides the re-
spondent’s decision on whether or not he or she would
receive the vaccine against COVID-19 (yes, no, or un-
certain), the questions regarded the following topics:
acknowledgement of the severity of COVID-19; amount
of information received from the dialysis team and from
the media; fear of side effects from the vaccine; confi-
dence in the health care system; and confidence in the
efficacy of the vaccine. Whether or not a respondent
had previously received an anti-influenza vaccine was
also recorded. Patients could add personal remarks at
the end of the questionnaire (available as supplementary
material). With the aim of avoiding intrusive questions,
the questionnaire posed nonspecific questions regarding
confidence in the system of care, dealing with the health
care system and scientists in general terms, and avoided
posing direct questions about confidence in the indi-
vidual patient’s dialysis team.
The final version was agreed on by a focus group. A
visual analog scale, which is a validated tool for med-
ical questionnaires, was used for indicating answers to
questions. The questionnaire was tested by the team of
dialysis nurses at CHM, and the final version was
submitted to the participating centers, to ensure that
the questions were correctly phrased in both French
and Italian. Because of the urgency of starting the
vaccination campaign, formal validation from groups of
nephrology patients was not sought. The survey was
conducted between January (Le Mans and Paris) and
March (Pavia and Cagliari) 2021, and the questionnaire
was administered to patients in paper format to be
filled during the dialysis session or at home, according
to the patient’s convenience.
The visual analog questions were analyzed as actual
number reported and summarized in 3 major scores:
low, 0 to 3; medium, 4 to 6; and high, 7 to 10.17
The analysis of the actual prevalence of anti–COVID-
19 vaccination (first dose considered) was performed
considering only individuals who did not have contra-
indications and were alive, and were being treated in
the same center as at the time of their first vaccine dose.4
Statistical Analysis
Statistical analysis was performed with SPSS, version
14 (IBM Corp, Armonk, NY, USA), and JASP, version
0.11.1 (JASP Team, Amsterdam, the Netherlands).
Descriptive analysis was conducted as appropriate; the
Shapiro-Wilk test was used to verify the normality
distribution of the data, and the Leven test was used to
verify homoscedasticity. Depending on distribution of
the data, the unpaired t test was used to compare 2
groups (eg, acceptance vs nonacceptance of vaccina-
tion), whereas the analysis of variance was used to
compare $3 groups (eg, comparing the study centers).
Otherwise, the Mann-Whitney test was applied to
compare 2 groups, whereas the Kruskal-Wallis test was
used for additional comparisons.
Categorial results were presented as size with a
percentage and compared with the chi-squared test or
the Fisher exact test for small subgroups.
Univariate logistic regressions were performed to test
the outcome of refusal to be vaccinated against COVID-19
in comparison to baseline data and answers to questions
on the questionnaire. receiver operating characteristic
curves, together with the Youden index, were used to
identify the best cutoff point for the continuous items
associated with the outcome (age only).
The outcome “refusal to be vaccinated against
COVID-19” was tested in a multivariate logistical
regression analysis. The explanatory variables were
chosen according to their clinical relevance or to the
significance in the univariate analysis. At baseline,
they were the following: age (dichotomized at Youden
index, 64 years), gender (female or male), and country
(Italy or France). As for the questionnaire entries,
because of the high degree of correlation between
questions inquiring about a specific aspect of vaccine
hesitancy (fear of the disease or acknowledgement of its
severity, confidence in the health care system and
scientists, information received, concerns about safety,
trust in the efficacy of the COVID-19 vaccine and
vaccines in general, and previous vaccination against
influenza), 1 sample question was chosen on the basis
of its higher statistical hazard ratio or clinical rele-
vance. The explanatory variables were dichotomized at
both the lowest values (scores 0-3) and the highest ones
(scores 7-10), thus building 2 separate models. A 2-
tailed alpha risk at 5% was considered statistically
significant.
Ethical Issues
The study was performed in compliance with the
Declaration of Helsinki. Patient participation was
voluntary. Permission for publication of the anony-
mous questionnaires and of anonymous general clinical
data was obtained when a completed questionnaire wasKidney International Reports (2021) -, -–-
Table 1. Baseline data of the study population: only patients who answered the questionnaire are included
Centers
P valueAll (N [ 417) Le Mans (n [ 128) Cagliari (n [ 136) Paris (n [ 44) Pavia (n [ 109)
% of questionnaires retrieved 87.8 93.4 96.4 54.3 94.0
Age, median (min-max) 69 (16–94) 70 (16–94) 67 (22–93) 52 (27–86) 73 (31–93) <0.001
Gender (woman), % 39.8 43.0 40.4 36.4 36.7 0.750
Charlson Comorbidity Index, median (min-max) 7 (2–16) 8 (2–16) 7 (2–16) 6 (2–12) 6 (2–13) 0.007
Patients born in a country other than the one of residence, n (%) 51 (12.2) 26 (20.3) 2 (1.5) 18 (40.9) 5 (4.6) <0.001
Education level, n (%) <0.001
Illiterate 7 (1.7) 3 (2.3) 3 (2.2) 1 (2.3) 0
Primary to middle school 238 (57.0) 75 (58.6) 67 (49.3) 6 (13.6) 90 (82.6)
Secondary school 104 (24.9) 33 (25.8) 49 (36.0) 15 (34.1) 7 (6.4)
University 68 (16.3) 17 (13.3) 17 (12.5) 22 (50.0) 2 (11.0)
Local language understanding, n (%) 0.666
3: Some difficulty 2 (0.5) 1 (0.8) 0 0 1 (0.9)
4: Almost complete understanding 7 (1.7) 3 (2.3) 1 (0.7) 0 3 (2.8)
5: Near–native speaker competence/bilingual 408 (97.8) 124 (96.9) 135 (99.3) 44 (100) 105 (96.3)
Activity, n (%) <0.001
Student 6 (1.5) 2 (1.6) 4 (2.9) 0 0
Unemployed 76 (18.2) 30 (23.4) 24 (17.7) 12 (27.3) 10 (9.2)
Working full or part time 66 (15.8) 3 (2.3) 29 (21.3) 18 (40.9) 16 (14.7)
Retired 269 (64.5) 93 (72.7) 79 (58.1) 14 (31.8) 83 (76.1)
Primary kidney disease, n (%) 0.025
Glomerulonephritis / systemic disease 80 (19.2) 22 (17.2) 29 (21.3) 11 (25.0) 18 (16.5)
Nephroangiosclerosis/diabetes 91 (21.8) 42 (32.8) 22 (16.2) 7 (15.9) 20 (18.4)
Polycystic kidney disease 38 (9.1) 9 (7.0) 9 (6.6) 4 (9.1) 16 (14.7)
Other 208 (49.9) 55 (43.0) 76 (55.9) 22 (50.0) 55 (50.5)
Renal replacement therapy vintage, yr, median (min-max) 3 (0–47) 2 (0–47) 3 (0–41) 5 (0–30) 3 (0–33) <0.001
Type of dialysis, n (%) <0.001
Peritoneal dialysis 56 (13.4) — 56 (41.2) — —
Hemodialysis 337 (80.8) 128 (100) 80 (58.8) 20 (45.5) 109 (100)
Home hemodialysis 24 (5.8) — — 24 (54.5) 0
Previous kidney transplant, n (%) 48 (11.5) 9 (7.0) 24 (17.7) 5 (11.4) 10 (9.2) 0.043
Vaccine hesitancy (refusal and undecided), n (%) 79 (18.9) 22 (17.2) 26 (19.1) 13 (29.6) 18 (16.5) 0.273
Vaccine refusal (refusal only), n (%) 47 (11.3) 21 (16.4) 10 (7.4) 11 (25.0) 5 (4.6) <0.001
P values in bold indicate significance.
S Blanchi et al.: COVID-19 Vaccine Hesitancy CLINICAL RESEARCHreturned. The study was approved by the ethics
committee at CHM in April 2021, and the ethics com-
mittees at the University of Cagliari and the Maugeri
Institute were also notified that the study was being
conducted in April 2021.RESULTS
Baseline Data
The baseline data of the patients who answered the
questionnaires are reported in Table 1, and the flow
chart of the study is presented in Figure 1, whereas
data on the patients who did not answer the ques-
tionnaires and their reasons for not participating are
reported in Supplementary Table S1. Supplementary
Figure S1 shows the study flow chart of each partici-
pating center.
In the context of a high response to the question-
naires (overall $85%), some baseline differences
emerged: the highest retrieval of questionnaires was in
Italy (Cagliari and Pavia), and the lowest in Paris, a
center that differs in significant respects from the others
in the study. The median age is lower, to some extent
reflecting the high number of patients on homeKidney International Reports (2021) -, -–-hemodialysis. Educational level is also higher, as is the
prevalence of patients who were born in a country other
than the one of residence (40%, double the percentage
in Le Mans, while Pavia and Cagliari had significantly
lower percentages of foreign-born patients). In keeping
with differences in age, the prevalence of patients
working was higher and the CCI was lower in Paris
compared with the other settings of study.
Reasons for declining to answer the survey were also
different: language barriers and dementia were the
main ones in Italy, whereas in Paris refusal was more
often due to lack of interest and/or lack of confidence
in why the survey was being conducted
(Supplementary Table 1). The situation in Le Mans was
intermediate. Language barriers and mental problems
accounted for some patients’ unwillingness to respond,
but for most of those who refused, this was the result of
personal or family convictions.
Quantitative Answers to the Questionnaires
and Relationship With the Acceptance of Anti-
influenza Vaccine
Table 2 summarizes the median scores recorded in
each center. The distribution of the answers in the5
Figure 1. Flow chart of the study population. Overall data.
CLINICAL RESEARCH S Blanchi et al.: COVID-19 Vaccine Hesitancy3 main scores (low-medium-high) is reported in
Supplementary Table 2. Supplementary Figure 2
shows the details of each answer to the
questionnaire.
In the context of a perception of a high risk of
being infected by SARS-CoV-2, the appreciation of
the severity of the disease was high (median score
9), without differences in the 4 settings. Patients
reported they had been extensively informed by the
media about the disease (median score 7) but had
received less information about the vaccine (median
score 6). Delivery of information from the dialysis
team was reported differently, with the lowest score
in Le Mans, where the administration of the ques-
tionnaire preceded the delivery of capillary oral and
written information on vaccination (including timing
and side effects). The highest scores were recorded
in Paris, where the questionnaires were proposed
almost at the same time as the vaccination campaign
began. Overall, patients stated they were favorable
to vaccination, as a general concept (median score
10), but their confidence in the efficacy of the
COVID-19 vaccine was a good deal lower (median
score 7).
Confidence in the way the health care system is
managing the crisis was not high in all centers (me-
dian score 5), whereas patients had more trust in
scientists (median score 7), with the highest score in
Le Mans (8) and the lowest in Paris (6). Although the
risk of side effects from the vaccine appears to be well
acknowledged (median score 5), this did not seem to
frighten patients on dialysis, who were not6
particularly worried about their personal well-being
(median score 3).
In the 2 French centers, the answers to questions
regarding the choice of COVID-19 vaccine were
straightforward, and only a minority of the patients
stated they were uncertain, whereas in Italy the num-
ber of uncertain individuals was higher than the
number of refusals. Interestingly, the prevalence of
vaccine hesitancy for COVID-19 was significantly lower
than those who indicated they would refuse to have an
influenza vaccine (18.9% vs. 35.7% P < 0.001).
Relationship Between Vaccine Hesitancy, Baseline
Data, and Response to the Questionnaire: Univariate
Analysis
Table 3 reports the results of the logistic regression
correlating refusal to be vaccinated, as stated on the
questionnaire, with clinical and demographic features
and with answers to other questions, dichotomized as
low versus all other scores.
The analysis confirms the importance of context: the
odds ratio (OR) for respondents living in France
refusing vaccination against SARS-COV-19 is 3.505;
being aged $64 years is associated with lower vaccine
hesitancy (OR: 0.248).
Conversely, it was found that gender, renal
replacement therapy vintage, having been exposed to
immunosuppressive treatments (because of glomerulo-
nephritis or transplantation), educational level, or be-
ing born in a country other than the one currently
residing in had no effect on answers to the
questionnaire.Kidney International Reports (2021) -, -–-
Table 2. Main scores recorded in the answers to the questionnaire and differences across the participating centers
Questions All
Centers
P valueLe Mans Cagliari Paris Pavia
n 417 128 136 44 109
Do you think you are a person at risk for COVID-19? (median, IQR) 7 (4) 7 (3) 7 (5) 6 (5.25) 7 (6) 0.856
Do you think that COVID-19 is a serious disease? (median, IQR) 9 (3) 9 (3) 9 (3) 10 (2) 9 (3) 0.376
Do you think you get enough information about COVID-19 from the media? (median, IQR) 7 (4) 8 (5) 7 (4) 9 (3) 7 (4) 0.001
Do you feel you have enough information about COVID-19 from the dialysis team? (median, IQR) 7 (4) 5 (6) 8 (4) 8 (5) 7 (4) <0.001
Do you think you have enough information about COVID-19 vaccines from the media? (median, IQR) 6 (4) 6 (5) 6 (4) 7 (4.5) 6 (4) 0.130
Do you feel you have enough information about COVID-19 vaccines from the dialysis team? (median, IQR) 6 (5) 3 (4) 7 (3) 8 (5) 7 (5) <0.001
Do you think it is complicated for you to get vaccinated against COVID-19? (median, IQR) 2 (6) 2 (5) 2 (4) 2 (6.75) 2 (5) 0.124
Do you think that COVID-19 vaccine is effective? (median, IQR) 7 (4) 5 (3) 8 (3) 7 (4) 8 (2) <0.001
Do you think that COVID-19 vaccines can cause serious side effects? (median, IQR) 5 (5) 5 (3.75) 5 (4.5) 5 (5.5) 4 (4) 0.102
Do you have any concerns about the safety of COVID-19 vaccines? (median, IQR) 3 (6) 5 (7) 2.5 (6) 4.5 (7.75) 3 (7) 0.713
In general, are you in favor of vaccination? (median, IQR) 10 (2) 10 (2.25) 10 (2) 9 (4.75) 10 (2) 0.294
In general, do you trust the authorities to manage the health crisis? (median, IQR) 5 (5) 5 (5) 5 (4) 5 (5.5) 5 (5) 0.817
In general, do you trust scientists to manage the health crisis? (median, IQR) 7 (3.25) 8 (4) 7 (2) 6 (4) 7 (4) 0.661
Vaccine hesitancy (refusal & undecided), n (%) 79 (18.9) 22 (17.2) 26 (19.1) 13 (29.6) 18 (16.5) 0.273
Vaccine hesitancy (refusal only), n (%) 47 (11.3) 21 (16.4) 10 (7.4) 11 (25.0) 5 (4.6) <0.001
Did you get your seasonal flu shot this year?, n (%) 0.083
Yes 261 (62.9) 90 (70.3) 81 (59.6) 25 (59.5) 65 (59.6)
No 148 (35.7) 34 (26.6) 55 (40.4) 17 (40.5) 42 (38.5)
I don’t know 6 (1.5) 4 (3.1) 0 0 2 (1.8)
IQR, interquartile range.
S Blanchi et al.: COVID-19 Vaccine Hesitancy CLINICAL RESEARCHConsidering that the information delivered from the
media was not sufficient was associated with a higher
probability of refusing vaccination, differently from
the amount of information delivered by the dialysis
team.
Confidence in getting the vaccine easily and not
being worried about side effects were associated with a
lower probability of vaccine refusal. On the contrary,
low confidence in vaccination (OR: 35.405) and not
having been vaccinated against influenza (OR: 25.650)
had the highest impact on vaccine refusal. Lack of
confidence in scientists and in the health care system
was significantly associated with vaccine refusal.
The same items were confirmed as significantly
associated with vaccine refusal considering the answers
on the 1 to 10 scale and dichotomizing them as high
scores (7–10) versus lower ones (0–6) (Supplementary
Tables S3 and S4).
Narrative Insights From the Questionnaire
Supplementary Table S5 reports some of the additional
comments patients wrote on the questionnaires.
Some points deserve to be underlined: the impor-
tance of the family in patients’ decisions, which holds
true for both large extended families (gypsies) and
smaller nuclear families (parents, children, and grand-
children); the idea that the attention the disease has
received is “much ado about nothing”; the fear that the
vaccine is not safe and that, therefore, for the moment
it may be wise to wait. A lack of confidence emerges
from some answers, whereas the importance of the
dialysis team is also clearly shown.Kidney International Reports (2021) -, -–-Relationship Between Vaccine Hesitancy, Baseline
Data, and Response to the Questionnaire: Multivariate
Analyses
In the multivariate analysis (Tables 4 and 5), vaccine
hesitancy was strongly correlated with country of
study, whereas age had little statistical significance;
confidence in the efficacy of the vaccine and having
had an anti-influenza vaccine were strongly associated
with vaccine hesitancy. Concerns about safety was an
important modulator of choice. High confidence in
scientists maintained its statistical significance in the
analysis, whereas the acknowledgment of the potential
severity of the disease was not associated with vaccine
hesitancy in either models. The residual analysis
demonstrated the goodness of fit of the statistical
models used (Supplementary Figures S3 and S4).
Relationship Between Vaccine Hesitancy and Actual
Administration of the Vaccine
The flowchart of the study population presented in
Figure 1, and in Supplementary Figure S1 for the in-
dividual centers, shows the relationship between the
choices indicated in the questionnaires and actual
administration of the vaccine, both for patients who
answered and those who did not answer the ques-
tionnaires. Out of 417 patients who answered the sur-
vey, 47 said they did not want to be vaccinated but,
eventually, 16 of them got vaccinated (Figure 1).
Overall, the responses given in the questionnaire
were strongly predictive of the patient’s choice. Lack
of response to the questionnaire was not associated
with vaccine hesitancy in the cases in which the7
Table 3. Univariate logistic regression correlating COVID-19 vaccine hesitancy (refusal in the questionnaire) with demographic data and other
answers
Univariate analysis Odds ratio
95% CI
P valueLower limit Higher limit
Country (France vs. Italy) 3.505 1.833 6.702 <0.001
Area (industrial vs. rural) 0.878 0.463 1.663 0.689
Age (yr) 0.973 0.955 0.991 0.003
Age (‡64 yr old)a 0.248 0.129 0.475 <0.001
Charlson Comorbidity Index (a.u.) 0.907 0.814 1.010 0.076
Charlson Comorbidity Index ($7) 0.730 0.398 1.341 0.310
Gender (female vs. male) 1.676 0.911 3.081 0.097
Dialysis vintage (yr) 1.020 0.985 1.056 0.257
No previous history of kidney transplantation 0.591 0.258 1.353 0.213
Glomerulonephritis / systemic disease 1.333 0.646 2.750 0.437
Being born in a country other than the one of residence 1.561 0.684 3.558 0.291
Educational level
University vs. fewer years of schooling 1.755 0.905 3.403 0.096
University and college to high school vs. lower degrees 1.724 0.937 3.171 0.080
Covid-19 vaccine acceptance on questionnaire
Do you think you are a person at risk for COVID-19? (low vs. medium and high) 1.922 0.965 3.695 0.055
Do you think that COVID-19 is a serious disease? (low vs. medium and high) 5.008 2.010 11.822 <0.001
Do you think you get enough information about COVID-19 from the media? (low vs. medium and high) 2.053 0.967 4.119 0.050
Do you feel you have enough information about COVID-19 from the dialysis team? (low vs. medium and high) 1.546 0.780 2.954 0.197
Do you think you have enough information about COVID-19 vaccines from the media? (low vs. medium and high) 2.954 1.547 5.590 <0.001
Do you feel you have enough information about COVID-19 vaccines from the dialysis team? (low vs. medium and high) 1.793 0.948 3.356 0.069
Do you think that COVID-19 vaccine is effective? (low vs. medium and high) 25.650 11.980 57.050 <0.001
In general, are you in favor of vaccination? (low vs. medium and high) 35.405 15.780 84.462 <0.001
In general, do you trust the authorities to manage the health crisis? (low vs. medium and high) 4.667 2.486 8.968 <0.001
Do you think it is complicated for you to get vaccinated against COVID-19? (low vs. medium and high) 0.185 0.086 0.370 <0.001
Do you think that COVID-19 vaccines can cause serious side effects? (low vs. medium and high) 0.163 0.048 0.416 <0.001
Do you have any concerns about the safety of COVID-19 vaccines? (low vs. medium and high) 0.098 0.033 0.231 <0.001
In general, do you trust scientists to manage the health crisis? (low vs. medium and high) 7.118 3.507 14.345 <0.001
Did you get your seasonal flu shot this year? (refusal) 4.451 2.351 8.776 <0.001
Statistically significant data are in bold.
aDefined using the Youden index calculated by means of the receiver operating characteristic curve.
CI, confidence interval.
CLINICAL RESEARCH S Blanchi et al.: COVID-19 Vaccine Hesitancydecision rested with the family or tutors (cognitive
impairment), or was the result of language barriers,
whereas declining to fill in the questionnaire was
associated with vaccine hesitancy.DISCUSSION
This study, analyzing the answers to a questionnaire
designed to assess vaccine hesitancy in more than 400
patients on dialysis, found a relatively low overall
prevalence of vaccine hesitancy in the dialysis popu-
lation, defined as present refusal to undergo COVID-19
vaccination in individuals without contraindications.
Only 11.3% of the patients who answered the dedi-
cated questionnaire stated they did not intend to have
the COVID-19 vaccine. There were, however, signifi-
cant differences, as the percentage ranged from 4.6%
(Pavia, industrial setting, northern Italy) to 25% in
Paris, France (Table 1). The actual figures (vaccines
administered) were similar (Figure 1, Supplementary
Figure S1), thus also indirectly validating this type of8
questionnaire for assessing patients’ opinions. Howev-
er, a questionnaire such as ours probably un-
derestimates vaccine hesitancy, as those who refused to
answer it were more likely not to have the COVID-19
vaccine (Figure 1). These differences are consistent
with previous studies of the general population that
found high vaccine hesitancy in France.8,9
These differences were at least partly expected on
account of the different degree of penetrance of COVID-
19 vaccine among health care workers, which was re-
ported as significantly lower in France, in particular in
Paris,18–20 than in Italy. In fact, in 2016, France and
Italy were the 2 countries with the highest rates of
vaccine safety skepticism.21 A European study con-
ducted in April 2020 in 7 countries showed that France
had the largest proportion of the population opposed to
a COVID-19 vaccine (10%) and the largest group of
people who had not decided whether or not they
would be vaccinated (28%). Denmark and the United
Kingdom were the countries with the largest propor-
tion of respondents who stated they would be willingKidney International Reports (2021) -, -–-













Lower vaccine hesitancy Higher vaccine
hesitancy
0.004 1.059
Age ($64 yr old) 0.646 0.271 1.537 0.319 1.120
Do you think that COVID-19 is a serious disease? (low vs. medium and high) 2.181 0.459 9.562 0.313 1.066
In general, do you trust scientists to manage the health crisis? (low vs. medium and
high)
2.419 0.827 6.669 0.095 1.177
Country (France vs. Italy) 2.461 1.050 5.929 0.040 1.087
Did you get your seasonal flu shot this year? (refusal) 2.624 1.095 6.475 0.032 1.162
Do you think that the COVID-19 vaccine is effective? (low vs. medium and high) 10.253 3.850 28.293 <0.001 1.236
CI, confidence interval; VIF, variance inflation factor.
Akaike information criterion: 183.41
See Supplementary Figure S2 for residuals of the model.
Statistically significant data are in bold.
S Blanchi et al.: COVID-19 Vaccine Hesitancy CLINICAL RESEARCHto be vaccinated (80%). In Italy, this rate was 74%.8
Similarly, in an international study conducted in
June 2020 in 19 countries, when asked “If a COVID-19
vaccine is proven safe and effective and is available, I
will take it,” only 58.89% of participants in France
answered that they would, versus 70.79% in Italy.9 It
is noteworthy, however, that the percentage of COVID-
19 vaccination in the 4 study centers was higher than
the national average for health care workers (100% of
the doctors and 100%, 80%, 87%, and 96% of the
nurses in Le Mans, Paris, Cagliari, and Pavia, respec-
tively). Because of a high incidence of SARS CoV2
infection in patients on dialysis,2,4 dialysis teams often
had to care for COVID-19 patients, which may explain
this difference.22
Differently from what has been described in the
overall population, gender and educational level did
not correlate with vaccine refusal; older age was asso-
ciated with lower vaccine refusal, but the difference
emerged only in the univariate analysis (Table 3).
Likewise, in the subset of the population that answered
the questionnaires (overall more than 85%), being born
in a country other than the one of residence (chosen as
a marker of belonging to an ethnic minority) did not
affect vaccine acceptance (Table 3), contrary to whatTable 5. Multivariate analysis with vaccine refusal as outcome and expla
Odds
ratio
Do you think that the COVID-19 vaccine is effective? (high vs. medium and low) 0.315
In general, do you trust scientists to manage the health crisis? (high vs. medium and
low)
0.387
Age ($64 yr old) 0.529
Do you think that COVID-19 is a serious disease? (high vs. medium and low) 0.579
Did you get your seasonal flu shot this year? (refusal) 1.884
Country (France vs. Italy) 2.290
Do you have any concerns about the safety of COVID-19 vaccines? (high vs. medium
and high)
8.192
CI, confidence interval; VIF, variance inflation factor.
Akaike information criterion: 185.74.
See supplementary figure 3 for residuals of the model.
Statistically significant data are in bold.
Kidney International Reports (2021) -, -–-has been reported for the general population.23–28
Furthermore, in a context of low vaccine hesitancy,
answers were not modulated by dialysis vintage, or by
exposure to immunosuppressive drugs (because of
previous transplantation or glomerular and systemic
kidney disease).
Patients were well aware of the risks and severity of
COVID-19. The question “Do you think that COVID-19
is a serious disease?” recoded a median score of 9,
without differences between centers (Table 2). This
perception of the seriousness of the infection was much
higher than that of the general population and may
explain the low rate of vaccine refusal, as it is a factor
associated with better acceptability of vaccina-
tion.10,12,23 Furthermore, patients were not worried
about vaccine availability (median score 2), probably
because in all centers the questionnaire was linked to
the vaccination campaign, and, in the context of
generic confidence in vaccines (median score 10), the
majority of the patients were not extremely concerned
about safety (median score 3), although they were, in
general, aware of the risks of side effects (median score
5) (Table 3).
Patients on dialysis are keen observers; their eval-









Lower vaccine hesitancy Higher vaccine
hesitancy
0.030 1.216
0.159 0.907 0.032 1.092
0.227 1.218 0.134 1.128
0.242 1.409 0.221 1.038
0.811 4.420 0.140 1.143
1.014 5.309 0.048 1.090
3.402 22.053 <0.001 1.064
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CLINICAL RESEARCH S Blanchi et al.: COVID-19 Vaccine Hesitancyhealth care team corresponded closely with what was
actually delivered in the different settings (no sys-
tematic information in Le Mans, where the question-
naire was intended to be the first step in the vaccine
campaign; in-depth information in Paris, where the
vaccine had been available earlier; and an intermediate
level in the 2 Italian centers). The level of information
did not, however, uniformly correlate with vaccine
hesitancy (Tables 4 and 5). A recent study in England
showed that information about COVID-19 vaccines did
not influence vaccination intentions.29
Concordance between the answers on the influenza
vaccine and on the COVID-19 vaccine raises questions
that merit further discussion: although, as expected,
not having received the influenza vaccine was asso-
ciated with a significantly higher probability of
refusing the COVID-19 vaccine (OR of about 7 for
refusing COVID-19 vaccine in the univariate analysis,
and of 2–3 in the 2 multiple regression models;
Tables 3–5), the prevalence of influenza refusal was
almost double compared with COVID-19 (Table 1).
This can be explained by a lower perceived severity
of seasonal influenza than COVID-19 by patients on
dialysis.30
Confidence in the health care system was relatively
low in all settings (median score 5; Table 2). However,
confidence in scientists (a generic term chosen to avoid
being intrusive and clearly alluding to the health care
team) was higher (median score 7; Table 2) and both
were correlated with vaccine hesitancy in the univar-
iate analysis, whereas in the multivariate analysis only
high confidence in the scientific community was asso-
ciated with a low probability of refusing the COVID-19
vaccine.
We consider that this is one of the most interesting
findings of our study, suggesting that confidence in the
scientific community is more important than having
been given information by the media or by a health
care team. In this regard, although we agree that from
an ethical point of view, information campaigns are
important for supporting choices, we have come to
think that they may be less relevant than confidence in
the role of science, a term that was chosen to indirectly
allude to the medical community. Lack of confidence in
the health care system was in fact identified as a major
determinant of vaccine hesitancy in the case of COVID-
19 and of other vaccines,10,19,26-28 and the low vaccine
acceptance of health care workers in some “difficult”
settings may also be evidence of this attitude.
In fact, vaccine hesitancy was not associated with
fear of COVID-19, nor with generic high hesitancy
about vaccines; patients on dialysis, probably like most
of our physicians, focused on the efficacy and security
of this specific vaccine, suggesting that educational10campaigns should be specifically addressed to these 2
points.
Interestingly, one-third of patients who expressed
their refusal to vaccination eventually got vaccinated,
suggesting that the personal belief expressed at the
beginning was not always consistent with the final
decision. However, the limited number of patients who
changed their decision after completing the question-
naire is too small to draw any conclusion.
The findings of a similar study, recently conducted
in 150 dialysis centers with 1515 patients in the United
States, were significantly different from ours.15
Younger patients, blacks, Native Americans, Pacific
Islanders, and women were more likely to state that
they would not be vaccinated. However, the authors
did not correlate vaccine hesitancy with the actual
percentage of patients in their sample who were sub-
sequently vaccinated. Moreover, only 14% of the
eligible participants answered the survey in the United
States, whereas our sample accounts for almost 88% of
the entire dialysis population in the 4 participating
centers.
Our study needs to be contextualized. It was per-
formed before the controversy over the side effects of
COVID-19 vaccines arose. Therefore, the responses
might have been different had it been done later.
Furthermore, it has several limitations: like all cross-
sectional studies, it only makes it possible to establish
associations, and cause-effect relationships are only
hypothetical. Although it enrolled more than 400 pa-
tients on dialysis, the number may be too low to
highlight other important differences relevant to the
rollout of a vaccine campaign for patients on dialysis.
Furthermore, many of the answers are mutually
related, and therefore a mathematical model may fail to
identify the leading ones and only suggest which as-
sociations may be of interest for understanding the
phenomenon of vaccine hesitancy in dialysis and for
suggesting targeted interventions. In addition, ques-
tionnaires were administered at different times in the 4
dialysis facilities, between January and March, and the
perception of vaccine efficacy and safety may change
over time as new information became available.
Although questions referred to health care workers and
the health care system in general, the help of caregivers
could have had an impact on patients’ answers. Finally,
no explanation on the reason for vaccine hesitancy was
available in cases that did not fill the questionnaire.
Within these limits, our study, the first one of its type
performed in Europe, showed that our dialysis popu-
lation is an interesting microcosm whose answers can
help us improve care and mutual confidence in the long
term, a major potential reinvestment of this difficult
experience.Kidney International Reports (2021) -, -–-
S Blanchi et al.: COVID-19 Vaccine Hesitancy CLINICAL RESEARCHIn conclusion, patients on dialysis have a keen un-
derstanding of COVID-19 risks. In the context of low,
but variable, vaccine hesitancy, this attitude is not
linked to educational level, age, or gender. Vaccine
hesitancy is closely associated with lack of confidence
in vaccine efficacy and concerns about safety. Patients
on dialysis are quite skeptical about the health care
system but generally trust scientists. The high accep-
tance of COVID-19 vaccination may be linked to this
trust, and this pattern should prompt us to reflect on
the fact that building a system of mutual trust is more
important than giving detailed information when
advising patients on important decisions, such as
whether or not to be vaccinated against COVID-19.DISCLOSURE




Table S1. General data on patients who did not answer the
questionnaires and main reasons for declining/not being
asked to participate in the study.
Table S2. Distribution of the quantitative answers
categorized into the three main scores (low: 0–3; medium
4–6; high 7–10).
Table S3. Univariate logistic regression correlating COVID-
19 vaccine hesitancy (refusal in the questionnaire).
Table S4. Univariate logistic regression correlating COVID-
19 vaccine hesitancy (refusal in the questionnaire)
dichotomized as high (7–10) versus low scores (0–6).
Table S5. Some thematic comments on the
questionnaires.
Figure S1. Flow chart of the study population: single center
data.
Figure S2. Detail of responses given in the questionnaire.
Figure S3. Residuals of the multivariate analysis with
vaccine refusal as outcome. Explanatory variables
dichotomized (low scores vs. others).
Figure S4. Residuals of the multivariate analysis with
vaccine refusal as outcome. Explanatory variables
dichotomized (higher scores vs. others).
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